Late Breaking Abstract - Protection by budesonide against clinically important deteriorations (CID) in patients with COPD is dependent on blood eosinophil counts (EOS)
Hoofdauteurs: | Bafadhel, M, Sing, D, Jenkins, C, Peterson, S, Bengtsson, T, Fageras, M |
---|---|
Formaat: | Conference item |
Gepubliceerd in: |
European Respiratory Society
2018
|
Gelijkaardige items
-
Adding budesonide to formoterol reduces risk of clinically important deteriorations (CID) in moderate to very severe COPD
door: Bafadhel, M, et al.
Gepubliceerd in: (2018) -
Modelling peripheral blood eosinophils to identify response to budesonide in COPD: a post-hoc analysis
door: Bafadhel, M, et al.
Gepubliceerd in: (2017) -
Investigating blood eosinophil count thresholds in patients with COPD
door: Russell, R, et al.
Gepubliceerd in: (2018) -
Late breaking abstract - Dose-ranging study of mepolizumab in eosinophilic COPD
door: Pavord, I, et al.
Gepubliceerd in: (2017) -
Case series of long-term macrolide therapy effect on eosinophil count in COPD
door: Asciak, R, et al.
Gepubliceerd in: (2017)